Situations of MTC in people dealt with with liraglutide, A different GLP-one receptor agonist, are already noted while in the postmarketing period; the data in these studies are inadequate to establish or exclude a causal partnership concerning MTC and GLP-one receptor agonist use in humans. There are already some experiences of thyroid cancer i